[Prophylactic vitamin K for vitamin K deficiency bleeding of the newborn].
BACKGROUND
The administration of vitamin K immediately after birth has shown a significant decrease in the incidence of newborn bleeding, but there is not enough evidence to determine the most appropriate method of administration. The objective of this review is to determine the effectiveness of orally administered vitamin K compared to the intramuscular route in the prevention of hemorrhagic disease of newborn (HDN).


METHODS
We conducted a systematic review of the main databases (Medline, Embase and Cochrane, among others) without limitation by date, language or type of study. Selected studies evaluated the efficacy and safety of vitamin K. Excluded were studies in pregnant women in preterm infants or patients with pathology. The validity of these studies was assessed by CASPe tools for systematic reviews and clinical trials.


RESULTS
Only two studies evaluated clinical aspects. They showed a reduction in the incidence of bleeding in the newborn after intramuscular prophylaxis with vitamin K. With regard to the oral route, different studies examined the effectiveness of vitamin K by determining biochemical parameters (factor X, prothrombin time and index, vitamin K1 in plasma and prothrombin antigen, among others) with inconclusive results regarding the route of administration and the number of doses.


CONCLUSIONS
There is sufficient evidence to support the effectiveness of a single intramuscular dose of vitamin K to prevent the classic form of HDN. With regard to late HDN and oral route, the results are inconclusive because the studies used biochemical indicators of effectiveness, which can not be correlated with the actual coagulation status of the newborn due to lack of scientific evidence.
Servicio de Investigación de la Agencia de Evaluación de Tecnologías Sanitarias, Sevilla, España. esther.martin.lopez.sspa@juntadeandalucia.es
J E
JE
Martín-López
A M
AM
Carlos-Gil
R
R
Rodríguez-López
R
R
Villegas-Portero
L
L
Luque-Romero
S
S
Flores-Moreno
D006801:Humans; D007231:Infant, Newborn; D014812:Vitamin K / Q000627:therapeutic use*; D006475:Vitamin K Deficiency Bleeding / Q000188:drug therapy*; D014815:Vitamins / Q000627:therapeutic use*
D014815:Vitamins; D014812:Vitamin K